Anti-BCMA CAR-T cell expansion appeared to peak in the peripheral blood in multiple myeloma patients, with a similar pattern compared to CAR-T cell products already approved for commercial use in lymphomas [22,23]. Here, TNFRSF17 is linked to plasma cell myeloma.